dexfenfluramine has been researched along with n-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ball, RG; Bateman, TJ; Chen, RZ; Debenham, JS; Fong, TM; Hale, JJ; Huo, P; Lao, J; Madsen-Duggan, CB; Reddy, VB; Shearman, LP; Shen, CP; Strack, AM; Stribling, DS; Tong, X; Tsou, N; Wang, J; Xiao, JC; Yan, L | 1 |
| Bedros, JR; Medvegy, M; Pados, G; Simonyi, G | 1 |
1 review(s) available for dexfenfluramine and n-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide
| Article | Year |
|---|---|
[The pharmacological treatment of obesity: past, present and future].
Topics: Amides; Anti-Obesity Agents; Anticonvulsants; Antidepressive Agents; Basal Metabolism; Benzazepines; Benzoxazines; Body Mass Index; Bridged Bicyclo Compounds, Heterocyclic; Ciliary Neurotrophic Factor; Clinical Trials as Topic; Combined Modality Therapy; Cyclobutanes; Dexfenfluramine; Fatty Acids; Female; Fenfluramine; Glucagon-Like Peptide 1; Human Growth Hormone; Humans; Intestinal Absorption; Lactones; Leptin; Life Style; Liraglutide; Male; Norepinephrine; Obesity; Obesity, Morbid; Orlistat; Piperidines; Pyrazoles; Pyridines; Receptor, Melanocortin, Type 4; Rimonabant; Satiation; Serotonin; Sodium-Glucose Transport Proteins; Sucrose; Thyroid Hormones | 2012 |
1 other study(ies) available for dexfenfluramine and n-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide
| Article | Year |
|---|---|
Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.
Topics: Animals; Anti-Obesity Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Body Weight; Cell Line; Cricetinae; Cricetulus; Crystallography, X-Ray; Dogs; Drug Inverse Agonism; Eating; Ether-A-Go-Go Potassium Channels; Glucuronides; Haplorhini; Hepatocytes; Humans; Mice; Mice, Knockout; Models, Molecular; Molecular Conformation; Pyrans; Pyridines; Rats; Receptor, Cannabinoid, CB1; Stereoisomerism; Structure-Activity Relationship | 2010 |